Insider Selling: Organogenesis Holdings Inc. (NASDAQ:ORGO) CEO Sells 86,531 Shares of Stock

Organogenesis Holdings Inc. (NASDAQ:ORGO – Get Rating) CEO Gary S. Gillheeney sold 86,531 shares of the company’s stock in a transaction on Wednesday, May 18th. The shares were sold at an average price of $5.46, for a total value of $472,459.26. Following the completion of the sale, the chief executive officer now owns 398,242 shares in the company, valued at $2,174,401.32. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website.

NASDAQ:ORGO traded up $0.09 during trading hours on Friday, reaching $5.98. The company had a trading volume of 714,311 shares, compared to its average volume of 1,053,485. The stock has a 50-day moving average of $7.04 and a two-hundred day moving average of $8.22. Organogenesis Holdings Inc. has a one year low of $5.30 and a one year high of $19.75. The firm has a market capitalization of $772.20 million, a PE ratio of 9.49 and a beta of 1.72. The company has a quick ratio of 2.54, a current ratio of 2.84 and a debt-to-equity ratio of 0.29.

Organogenesis (NASDAQ:ORGO – Get Rating) last announced its earnings results on Tuesday, May 10th. The company reported $0.01 EPS for the quarter, missing the consensus estimate of $0.05 by ($0.04). The business had revenue of $98.12 million for the quarter, compared to the consensus estimate of $96.15 million. Organogenesis had a return on equity of 41.46% and a net margin of 18.34%. During the same quarter in the previous year, the company posted $0.07 EPS. As a group, sell-side analysts expect that Organogenesis Holdings Inc. will post 0.4 earnings per share for the current year.

Several hedge funds have recently made changes to their positions in the company. BlackRock Inc. grew its holdings in shares of Organogenesis by 17.1% during the first quarter. BlackRock Inc. now owns 9,652,188 shares of the company’s stock worth $73,551,000 after purchasing an additional 1,412,356 shares during the last quarter. Deerfield Management Company L.P. Series C grew its holdings in shares of Organogenesis by 13.3% during the fourth quarter. Deerfield Management Company L.P. Series C now owns 8,456,876 shares of the company’s stock worth $78,142,000 after purchasing an additional 994,333 shares during the last quarter. State Street Corp grew its holdings in shares of Organogenesis by 33.0% during the fourth quarter. State Street Corp now owns 5,400,860 shares of the company’s stock worth $49,904,000 after purchasing an additional 1,341,450 shares during the last quarter. Vanguard Group Inc. lifted its stake in shares of Organogenesis by 7.0% during the first quarter. Vanguard Group Inc. now owns 4,605,257 shares of the company’s stock valued at $35,092,000 after acquiring an additional 303,243 shares during the period. Finally, Granahan Investment Management Inc. MA lifted its stake in shares of Organogenesis by 0.6% during the third quarter. Granahan Investment Management Inc. MA now owns 2,122,005 shares of the company’s stock valued at $30,217,000 after acquiring an additional 13,553 shares during the period. Institutional investors own 38.41% of the company’s stock.

Separately, Zacks Investment Research cut Organogenesis from a “hold” rating to a “sell” rating in a research report on Saturday, May 14th. One research analyst has rated the stock with a sell rating and three have assigned a buy rating to the stock. Based on data from MarketBeat, Organogenesis presently has a consensus rating of “Buy” and a consensus price target of $19.75.

About Organogenesis (Get Rating)

Organogenesis Holdings Inc, a regenerative medicine company develops, manufactures, and commercializes solutions for the advanced wound care, and surgical and sports medicine markets in the United States. The company's advanced wound care products include Affinity, an amniotic membrane wound covering in which viable cells growth factors/cytokines, and ECM proteins in the native tissue are preserved; Apligraf, a bioengineered living cell therapy that produce spectrum of cytokines and growth factors; Dermagraft, a bioengineered product that produces human collagen, ECM, proteins, and cytokines; NuShield, a wound covering tissue includes both amnion and chorion membranes for spongy/intermediate layer intact; PuraPly , a antimicrobial barrier that enables conformability and fluid drainage; and Novachor, an amniotic membrane wound covering in which viable cells, growth factors/cytokines, and ECM proteins are preserved.

Recommended Stories